Semaglutide News and Research

Latest Semaglutide News and Research

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

Whether antidiabetic medications could potentially be used as disease-modifying osteoarthritis drugs or DMOADs for the therapeutic management of osteoarthritis.

21 Aug 2024

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

On May 13, Sen. Bernie Sanders (I-Vt.) published an open letter to Novo Nordisk on the front page of a leading Danish newspaper, urging the hometown company to live up to its altruistic standards by lowering U.S. prices for its blockbuster diabetes and weight loss drugs.

8 Aug 2024

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with private insurance.

2 Aug 2024

$Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction$

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

A new small study led by Johns Hopkins Medicine researchers and published July 25th in the journal Nature Cardiovascular Research has revealed the impact of obesity on muscle structure in patients having a form of heart failure called heart failure with a preserved ejection fraction (HFpEF).

1 Aug 2024

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

Researchers reviewed studies on dietary impacts of GLP-1 and GIP/GLP-1 receptor agonists in obesity and T2D patients, finding significant caloric reduction but limited evaluation of dietary composition.

29 Jul 2024

New scoring system enhances identification of HFpEF patients

A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

29 Jul 2024

Semaglutide may reduce smoking risks for diabetes patients

Semaglutide shows promise in reducing tobacco use disorder-related health encounters in patients with type 2 diabetes, but further clinical trials are needed to confirm its efficacy.

29 Jul 2024

Pharmacist cautions against self-medicating with ozempic for dementia risk reduction

“According to the latest figures released by the NHS, dementia diagnosis is at a record high in England.

29 Jul 2024

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

Researchers highlight the unprecedented success of GLP-1-based multi-receptor drugs in achieving substantial weight loss and improved health outcomes, potentially replacing bariatric surgery for obesity treatment.

28 Jul 2024

How diet affects metabolism and the gut microbiome

In a recent review, researchers explored advances in molecular nutrition, focusing on pharmaceutical and dietary interventions for energy balance and their interactions with the gut microbiome. They also discussed emerging dietary patterns and the implications of microbiome research on nutrition.

28 Jul 2024

Older adults show interest in deprescribing, study reveals

More than 82% of Americans age 50 to 80 take one or more kinds of prescription medication, and 80% of them say they'd be open to stopping one or more of those drugs if their health care provider gave the green light, a new University of Michigan study shows.

24 Jul 2024

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself "at my ideal body weight," with his cholesterol below 200 for the first time in 20 years. "I feel fantastic," he said.

23 Jul 2024

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

The advantages of glucagon-like peptide-1 (GLP-1) medicines beyond glycemic and weight control.

23 Jul 2024

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)-;prescription medications sold under popular drug names like Ozempic and Wegovy-;in the United States.

22 Jul 2024

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

In a Perspective, Daniel Drucker highlights the growing body of evidence that hints at the potential of glucagon-like peptide-1 (GLP-1)-based medications in treating conditions other than diabetes and obesity, including cardiovascular disease and neurodegenerative disorders.

18 Jul 2024

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Researchers evaluated the 12-month neurological and psychiatric outcomes of semaglutide use in patients with type 2 diabetes mellitus using a propensity-score matched cohort.

17 Jul 2024

Semaglutide News and Research

Latest Semaglutide News and Research

Study finds potential for antidiabetic drugs to modify osteoarthritis risk

How little Denmark got homegrown giant Novo Nordisk to lower ozempic prices

Public insurance recipients less likely to receive diabetes and obesity drug, study reveals

Study reveals obesity's impact on muscle structure in heart failure with preserved ejection fraction

Weight loss guaranteed! But what impact on your diet? A review of GLP-1 and GIP/GLP-1 interventions

New scoring system enhances identification of HFpEF patients

Semaglutide may reduce smoking risks for diabetes patients

Pharmacist cautions against self-medicating with ozempic for dementia risk reduction

GLP-1-based polyagonists: A promising weight loss alternative to bariatric surgery

How diet affects metabolism and the gut microbiome

Older adults show interest in deprescribing, study reveals

Why millions are trying FDA-authorized alternatives to big pharma’s weight loss drugs

Beyond the anti-obesity benefits of glucagon-like peptide-1 drugs

Study identifies trends in the use of glucagon-like peptide-1 receptor agonists

Exploring the expanding horizons of GLP-1 therapies beyond diabetes and obesity

Semaglutide shows no higher 12-month risk of adverse neuropsychiatric outcomes than other antidiabetic drugs, study suggests

Study shows oral semaglutide matches DPP-4i in adherence and persistence for type 2 diabetes

Harnessing brain proteins for enhanced diabetes and weight-loss drugs

SH2B1 gene defends against obesity via the paraventricular hypothalamus

Twincretin drug Tirzepatide shows unmatched efficacy in weight loss and diabetes management

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Semaglutide News and Research

Latest Semaglutide News and Research

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Newsletters you may be interested in